

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EVEREST MEDICINES

云 頂 新 耀

Everest Medicines Limited

雲 頂 新 耀 有 限 公 司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1952)

GRANT OF SHARE OPTIONS AND SHARE AWARDS

GRANT OF SHARE OPTIONS

This announcement is made pursuant to Rule 17.06A of the Listing Rules. The Board announces that on 6 May 2021, the Company granted 776,518 Options to 2 Grantees under the Post-IPO Share Option Scheme. The details of the Options granted to the Grantees are as follows:

Date of grant:	6 May 2021
Exercise price of the Options granted:	HK\$67.97 per Share
Number of Options granted:	776,518
Market price of the Shares on the date of grant:	HK\$66.25 per Share
Validity period of the Options:	ten years after the date of grant

None of the grant of Options will be subject to approval by the Shareholders, and none of the Grantees is a Director, chief executive or substantial shareholder (as defined in the Listing Rules) of the Company or an associate (as defined in the Listing Rules) of any of them.

The grant of Options enable the Company to attract, retain, incentivize, reward and remunerate the Grantees, and encourage them to work towards enhancing the value of the Company and the Shares for the benefit of the Company and Shareholders as a whole.

GRANT OF SHARE AWARDS

On a voluntary basis, the Board announces that on 6 May 2021, the Company granted 445,076 Awards to 2 Grantees under the Post-IPO Share Award Scheme.

Each of the Awards is granted, among other terms, for nil consideration, and represents the right to receive one Share on the date the Award vests. The market price of the Shares on the date of grant was HK\$66.25 per Share.

None of the grant of Awards will be subject to approval by the Shareholders, and none of the Grantees is a Director, chief executive or substantial shareholder (as defined in the Listing Rules) of the Company or an associate (as defined in the Listing Rules) of any of them.

The Post-IPO Share Award Scheme does not constitute a share option scheme pursuant to Chapter 17 of the Listing Rules and is a discretionary scheme of the Company.

The grant of Awards enable the Company to attract, retain, incentivize, reward and remunerate the Grantees, and encourage them to work towards enhancing the value of the Company and the Shares for the benefit of the Company and Shareholders as a whole.

DEFINITIONS

“Award(s)”	awards(s), being a contingent right to receive Shares awarded under the Post-IPO Share Award Scheme
“Board”	the board of Directors
“Company”	Everest Medicines limited, an exempted company with limited liability incorporated in the Cayman Islands on 14 July 2017
“Directors”	the directors of the Company
“Grantees”	the employees of the Company and its subsidiaries who were granted Options and/or Awards in accordance with the Post-IPO Share Option Scheme and/or the Post-IPO Share Award Scheme respectively on 6 May 2021
“HK\$”	Hong Kong dollar, the lawful currency of the Hong Kong Special Administrative Region of the People’s Republic of China
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“Option(s)”	option(s) to subscribe for or acquire Shares which is/are granted under the Post-IPO Share Option Scheme

“ Post-IPO Share Award Scheme ”	the post-IPO share award scheme adopted by the Shareholders on 21 September 2020
“ Post-IPO Share Option Scheme ”	the post-IPO share option scheme adopted by the Shareholders on 21 September 2020
“ Shareholders ”	holder(s) of Shares in the Company
“ Shares ”	ordinary shares in the share capital of the Company with a par value of US\$0.0001 each
“ US\$ ”	U.S dollars, the lawful currency of the United States of America

By Order of the Board
Everest Medicines Limited
Wei Fu
Chairman and Executive Director

Hong Kong, 7 May 2021

As at the date of this announcement, the board of directors of the Company comprises Mr. Wei Fu as Chairman and Executive Director, Dr. Kerry Levan Blanchard, Mr. Ian Ying Woo and Mr. Xiaofan Zhang as Executive Directors, Mr. Yubo Gong and Ms. Lan Kang as Non-executive Directors, and Mr. Bo Tan, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.